Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in at-risk pregnancies for prevention of severe FNAIT
NL-OMON59152Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fetomaternal alloimmune thrombocytopenia (FMAIT) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Composite adverse fetal or neonatal outcome. Planned start Feb 2024; status: withdrawn.
02
Drugs
nipocalimab
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on NL-OMON59152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59152.